Next 10 |
150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications Nutriband raised $8.4 million in a private placement to...
2024-05-03 11:54:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nutriband (NASDAQ: NTRB ) just reported results for the fourth quarter of 2023. Nutriband reported earnings per share of -23 cents. The company reported revenue of $52...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Nutriband (NASDAQ: NTRB, NTRBW) , a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. A...
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB) , a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected IBN , a multifaceted financial news and publishing company for private and publi...
Nutriband (NASDAQ: NTRB, NTRBW) , a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl ha...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing Nutriband working to complete the commercial scale-up prior to performing the pivotal laboratory assessment and clinical study required for FDA approval AV...
Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is...
Nutriband (NASDAQ: NTRB, NTRBW) today announced that following its engagement by Fit For Life Group (“FFL”), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive supplier agreement for FFL’s new product launch under one of its top brands...
News, Short Squeeze, Breakout and More Instantly...
150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications Nutriband raised $8.4 million in a private placement to...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...